DS
NVLN

David Shaw’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

David Shaw’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-29,417
Closed -$103K – 3983
2018
Q1 		$103K Sell
29,417
-10,790
-27% -$45.7K ﹤0.01% 3387
2017
Q4 		$125K Buy
40,207
+4,230
+12% +$20.3K ﹤0.01% 3480
2017
Q3 		$253K Buy
35,977
+6,878
+24% +$55.1K ﹤0.01% 3208
2017
Q2 		$269K Sell
29,099
-18,421
-39% -$177K ﹤0.01% 3071
2017
Q1 		$510K Sell
47,520
-25,000
-34% -$255K ﹤0.01% 2726
2016
Q4 		$611K Buy
+72,520
New +$642K ﹤0.01% 2739

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

David Shaw's NVLN Position: Q2 2018 in Review

David Shaw sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 29,417 shares — an estimated $103K sold.

David Shaw first reported a position in NVLN in Q4 2016 and held it in 6 quarters. The position peaked at $611K in Q4 2016. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • David Shaw reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • David Shaw sold 29,417 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $103K.
  • David Shaw first reported a position in Novelion Therapeutics Inc. Common Shares in Q4 2016 and held it in 6 quarters.
  • David Shaw's Novelion Therapeutics Inc. Common Shares position peaked at $611K in Q4 2016.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on D.E. Shaw & Co's 13F filing for Q2 2018, filed 14 Aug 2018.